• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

IJERPH, Vol. 16, Pages 326: The Risk of Stroke in Kidney Transplant Recipients with End-Stage Kidney Disease
Ju Wu Chia-Hung Kao Background: The incidence of stroke after kidney transplantation is poorly understood. Our study aimed to determine the incidence and predictors of stroke as well as mortality from stroke in kidney transplant recipients (KTRs). Methods: This retrospective cohort study used the National Health Insurance Research Database in Taiwan to study KTRs (N = 4635), patients with end-stage renal disease (ESRD; N = 69,297), and patients from the general population who were chronic kidney disease (CKD)-free and matched by comorbidities (N = 69,297) for the years 2000 through 2010. The risk of stroke was analyz...
Source: International Journal of Environmental Research and Public Health - January 24, 2019 Category: Environmental Health Authors: Shih-Ting Huang Tung-Min Yu Ya-Wen Chuang Mu-Chi Chung Chen-Yu Wang Pin-Kuei Fu Tai-Yuan Ke Chi-Yuan Li Cheng-Li Lin Ming-Ju Wu Chia-Hung Kao Tags: Article Source Type: research

The correlation between CVP and SVV and intraoperative minimal blood loss in living donor hepatectomy
Blood loss in liver surgery is found to be correlated with central venous pressure (CVP). The aim of the current retrospective study is to find out the cut of value of CVP and stroke volume variation (SVV), which may increase the risk of having intraoperative blood loss more than 100 ml during living liver donor hepatectomy.
Source: Transplantation Proceedings - April 11, 2018 Category: Transplant Surgery Authors: Tsung-Hsiao Shih, Yu-Huan Tsou, Chia-Jung Huang, Chao-Long Chen, Kwok-Wai Cheng, Shao-Chun Wu, Sheng-Chun Yang, Sin-Ei Juang, Chiu-En Huang, Ying-En Lee, Bruno Jawan, Chih-Hsien Wang, Kow-Aung Chang Source Type: research

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
CONCLUSIONS: There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and high risk of bias. We have identified an area of large uncertainty for a group of patients who account for most of those diagnosed as having CKD.PMID:37466151 | DOI:10.1002/14651858.CD007751.pub3
Source: Cochrane Database of Systematic Reviews - July 19, 2023 Category: General Medicine Authors: Tess E Cooper Claris Teng David J Tunnicliffe Brydee A Cashmore Giovanni Fm Strippoli Source Type: research